Indocyanine green and methylene blue dye guided sentinel lymph node biopsy in patients with penile cancer (PeCa): results of 50 inguinal basins assessed at a single institution in India

Plain-language guide to PMID 39331184 (2024): observational study of Methylene blue (non-peptide stack partner) in 25 patients.

Key Facts

PMID: 39331184
Journal: World journal of urology
Year: 2024
Study type: Observational Study
Authors: Amaresh M et al. (6 authors)
DOI: 10.1007/s00345-024-05250-4

What This Study Did, in Plain Language

What Was Tested

This observational study looks at Methylene blue (non-peptide stack partner).

The primary aim of this study was to validate the reliability, sensitivity and safety profile of novel combination of ICG- methylene blue dye as an SN tracer for PeCa.

Who Took Part

According to the abstract, 25 patients were involved.

By PubMed's age tags, the people studied were adults, middle-aged adults and older adults, men only.

This is a validation and non-randomised prospective observational study involving 25 patients (50 inguinal basins) who underwent SLNB where in ICG and methylene blue were used for localisation.

The patients with clinically node negative groins were recruited in the study.

How the Study Was Run

SNs were identified intraoperatively using near infrared fluorescence imaging (NIRF Imaging system, SPY-PHI, Stryker, Sweden) and blue dye.

The numbers of SNs identified by each tracer and the rates of complications and nodal recurrence during the followup.

What Was Measured

The subject headings attached to it are Methylene Blue, Indocyanine Green, Sentinel Lymph Node Biopsy, Penile Neoplasms, Coloring Agents, Inguinal Canal and India.

The authors tagged it with the keywords Dual dye technique, Dynamic sentinel Lymphnode biopsy, Node negative groin and Penile cancer.

What This Means in Plain Language

This is an observational study of Methylene blue (non-peptide stack partner) in 25 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Results are reported in around 8 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2024 (World journal of urology), a journal based in Germany.

More context: the Methylene blue (non-peptide stack partner) compound page, all human trials.

Our Notes on the Compound

Methylene blue (non-peptide stack partner): Described as an electron cycler, not just a dye.

Methylene blue (non-peptide stack partner) in the library

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.